Literature DB >> 9063854

The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma.

A Kawai1, S Sugihara, T Kunisada, M Hamada, H Inoue.   

Abstract

The relationship between dose intensity of cytotoxic agents and therapeutic results was examined in a retrospective analysis of 32 patients with non-metastatic high-grade osteosarcoma of the extremities. The average dose intensities of individual agents were 9.8 mg/m2/week for doxorubicin, 1.2 g/m2/week for methotrexate, and 10.5 mg/m2/week for cisplatinum. The dose intensities of doxorubicin and methotrexate were significantly correlated with the clinical results, while that of cisplatinum was not. These results indicate that maximal dose intensification of doxorubicin and methotrexate is an important determinant of treatment outcome for patients with osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9063854     DOI: 10.1007/bf00573443

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  12 in total

Review 1.  Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.

Authors:  N V Cheung; G Heller
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

2.  The treatment of localized osteosarcoma of the extremities: the Italian experience. Studies of the National Research Council.

Authors:  P Picci; G Bacci; P Ruggieri; G Madon; G Paolucci; M Marangolo; M Mercuri; R Biagini; N Fabbri; R Casadei
Journal:  Ann Oncol       Date:  1992-04       Impact factor: 32.976

3.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

Review 4.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

5.  High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results.

Authors:  N Jaffe; A Goorin; M Link; H Watts; E Frei; G Vawter; K E Fellows; G P Beardsley; H T Abelson
Journal:  Cancer Treat Rep       Date:  1981

6.  Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.

Authors:  R E van Rijswijk; C Haanen; A W Dekker; A J de Meijer; J Verbeek
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

Review 7.  Dose intensity in cancer chemotherapy.

Authors:  D J Dodwell; H Gurney; N Thatcher
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

8.  Rotation-plasty for childhood osteosarcoma of the distal part of the femur.

Authors:  R Kotz; M Salzer
Journal:  J Bone Joint Surg Am       Date:  1982-09       Impact factor: 5.284

9.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.

Authors:  W Hryniuk; M N Levine
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

10.  The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively.

Authors:  G Bacci; P Picci; M Avella; D Dallari; S Ferrari; R Prasad; M Di Scioscio; C Malaguti; P Caldora
Journal:  J Chemother       Date:  1990-04       Impact factor: 1.714

View more
  1 in total

1.  Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Authors:  L E Selmic; J H Burton; D H Thamm; S J Withrow; S E Lana
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.